Teijin Ltd. engages in the management of its group companies that are involved in the environment and energy, safety and protection, information and electronics, transportation, and healthcare businesses. It operates through the following segments: Materials, Healthcare, and Others. The Materials segment handles the manufacture and sale of polyester, aramid, and carbon fiber products as well as plastic and resin products from polycarbonate resin and polyester film. The Healthcare segment deals with the manufacture and sale of pharmaceuticals and home medical equipment. It also provides home healthcare services. The Others segment offers information technology services. The company was founded by Seita Kumura, Itsuzo Hata, and Naokichi Kaneko on June 17, 1918 and is headquartered in Osaka, Japan.

Tianjin Tianshi Biological Development Co., Ltd., established on 1998-03-27, Business scope includes licensed projects:food production;Health food production;food sales;Cosmetic production;beverage production;Production of tea products.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments)General project:Engineering and Technology Research and Experimental Development;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion(Development and application of technology without human stem cells,Development and application of human gene diagnosis and treatment technology);Manufacturing of daily chemical products;Sales of daily chemical products;Cosmetics Retail;Cosmetics Wholesale;Personal Hygiene Sales;General merchandise sales;Instrument Manufacturing;Instrument sales;Metal Structure Sales;Fabrication of Metal Structures;business training(Does not include education and training,Vocational skills training and other licensed training);Machinery and Equipment Leasing;Computer and communication equipment rental;Storage equipment rental service;Transportation equipment rental service;Office equipment rental service;Special equipment rental;Stationery equipment rental;Information Technology Consulting Services.(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)(Not allowed to invest<Negative List for Foreign Investment Access>Fields where foreign investment is prohibited).

Takara Bio Inc., develops, manufactures, and distributes a wide range of life science reagents and kits under the Takara®, Clontech®, and Cellartis® brands. Key products include SMART® cDNA synthesis kits for a variety of samples and applications, including NGS; high-performance qPCR and PCR reagents (including the Takara Ex Taq®, Takara LA Taq®, Titanium®, and Advantage® enzymes); Cellartis stem cells and stem cell reagents; RT enzymes and SMART library construction kits; the innovative In-Fusion® cloning system; Guide-it™ gene editing tools; Tet-based inducible gene expression systems; and Living Colors® fluorescent proteins. These and other products support applications including NGS; gene discovery, regulation, and function studies; protein expression and purification; RNAi, gene editing, and stem cell studies; and plant and food research

Enzo Biochem, Inc. is an integrated diagnostics, clinical lab, and life sciences company, which focuses on delivering and applying advanced technology capabilities to produce affordable reliable products and services that enable customers to meet their clinical needs. It operates through the following segments: Products, Clinical Services, and Therapeutics. The Products segment develops, manufactures, and markets products to research and pharmaceutical customers. The Clinical Services segment provides diagnostic services to the health care community. The Therapeutics segment conducts research and development activities for therapeutic drug candidates. The company was founded by Elazar Rabbani, Barry W. Weiner and Shahram K. Rabbani in 1976 and is headquartered in New York, NY.

Manufactures petrochemicals, pharmaceuticals, functional materials and plastic-based products

Part of Tiens Investment Holdings Group Ltd., Tiens Biotech Group, Inc. is a Chinese company located in Tianjin that develops and distributes pharmaceutical products.

Smithkline Beckman Corp, part of GSK Plc, is an American company located in Philadelphia, PA, involved in pharmaceutical preparations. On July 27, 1989 Smithkline Beecham Plc acquired Smithkline Beckman Corp for $16,082.37 million.

Biomep is a medicine and food supplement product manufacturer with ingredients and processes that exceed the standards. They have service and a wide range of products. They always have the most up-to-date technical capacity and professional ethics and are invariably reliable in the fulfilment of their commitments. An online inquiry form is available on the company's website.

Takara Shuzo Co. Ltd. manufactures and markets alcoholic beverages. Its products include alcoholic beverages, raw alcohol, health drinks, and seasonings. The company was founded in 1925 and is headquartered in Kyoto, Japan.

Alexion Pharmaceuticals is a biopharmaceutical company, which is engaged in the discovery, development, and commercialization of biologic therapeutic products aimed at treating patients with severe and life-threatening disease states, including hematologic, kidney and neurologic diseases, transplant rejection, cancer, and autoimmune disorders. Its marketed product Soliris (eculizumab) is a therapy approved for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH). In April 2009 and August 2009, the United States food and drug administration (FDA) and the European Commission (E.C.), respectively, granted Soliris orphan drug designation for the treatment of patients with atypical Hemolytic Uremic Syndrome (aHUS). In December 2009, its Rhode Island manufacturing facility received regulatory approval from the E.C. Or the production of Soliris.

Athersys is a biopharmaceutical company that discovers and develops therapeutic products to treat several disease indications. The company's product development portfolio includes MultiStem, a stem cell product, that is being developed as a treatment for multiple disease indications, is being evaluated in two ongoing clinical trials, and has been authorized for use in a third clinical trial. In addition, Athersys develops pharmaceuticals to treat indications such as obesity, certain cognitive and attention disorders, narcolepsy, or other forms of excessive daytime sleepiness.

Osteometer Biotech AS is a Danish private company located in Herlev that develops treatments for bone disorders.

PEPTIDE INSTITUTE is a Pharmaceutical company.

LG Life Sciences Ltd. engages in the development, production and marketing medicine and fine chemicals. Its products include growth hormone products, arthritis medicine, diabetes medicine, cosmetic surgery products, hypertension treatment, synthetic medicinal raw materials, and pesticide raw material. The company was founded on August 1, 2002 and is headquartered in Seoul, South Korea.

Enobia Pharma, Inc. develops therapies to treat patients with ultra-rare and life-threatening genetic metabolic bone disorders. Its lead product candidate, asfotase alfa or ENB-0040, is a treatment for hypophosphatasia—a life-threatening disease that can cause skeletal deformity, severe muscle weakness and progressive damage to vital organs. The company was founded in 1997 and is headquartered in Montreal, Canada.

Eisai Co., Ltd. engages in the development, manufacture, and sale of prescription medicines and over-the-counter products. It operates through the Pharmaceutical Products Business and Other Business segments. The Pharmaceutical Products Business segment handles prescription and generic drugs, diagnostics, and consumer healthcare business in Japan, which manages over-the-counter drugs. The Other Business segment deals with food additives and chemicals. The company was founded by Toyoji Naito in November 1936 and is headquartered in Tokyo, Japan.